Free Access
Issue
Med Sci (Paris)
Volume 36, Octobre 2020
Les jeunes contre le cancer : la Ligue en soutien
Page(s) 42 - 46
DOI https://doi.org/10.1051/medsci/2020197
Published online 14 October 2020
  1. Shang S, Hua F, Hu ZW. The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 2017 ; 8 : 33972–33989. [CrossRef] [PubMed] [Google Scholar]
  2. Lhoumeau AC, Martinez S, Boher JM, et al. Overexpression of the promigratory and prometastatic PTK7 receptor is associated with an adverse clinical outcome in colorectal cancer. PLoS One 2015 ; 10 : e0123768. [CrossRef] [PubMed] [Google Scholar]
  3. Daulat AM, Borg JP. Wnt/planar cell polarity signaling: new opportunities for cancer treatment. Trends Cancer 2017 ; 3 : 113–125. [CrossRef] [PubMed] [Google Scholar]
  4. Peradziryi H, Tolwinski NS, Borchers A. The many roles of PTK7: a versatile regulator of cell-cell communication. Arch Biochem Biophys 2012 ; 524 : 71–76. [CrossRef] [PubMed] [Google Scholar]
  5. Martinez S, Scerbo P, Giordano M, et al. The PTK7 and ROR2 protein receptors interact in the vertebrate WNT/planar cell polarity (PCP) pathway. J Biol Chem 2015 ; 290 : 30562–30572. [CrossRef] [PubMed] [Google Scholar]
  6. Puppo F, Thome V, Lhoumeau AC, et al. Protein tyrosine kinase 7 has a conserved role in Wnt/beta-catenin canonical signalling. EMBO Rep 2011 ; 12 : 43–49. [Google Scholar]
  7. Lu X, Borchers AG, Jolicoeur C, et al. PTK7/CCK-4 is a novel regulator of planar cell polarity in vertebrates. Nature 2004 ; 430 : 93–98. [Google Scholar]
  8. Lin Y, Zhang LH, Wang XH, et al. PTK7 as a novel marker for favorable gastric cancer patient survival. J Surg Oncol 2012 ; 106 : 880–886. [Google Scholar]
  9. Prebet T, Lhoumeau AC, Arnoulet C, et al. The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood 2010 ; 116 : 2315–2323. [Google Scholar]
  10. Ataseven B, Angerer R, Kates R, et al. PTK7 expression in triple-negative breast cancer. Anticancer Res 2013 ; 33 : 3759–3763. [PubMed] [Google Scholar]
  11. Meng L, Sefah K, O’Donoghue MB, et al. Silencing of PTK7 in colon cancer cells: caspase-10-dependent apoptosis via mitochondrial pathway. PLoS One 2010 ; 5 : e14018. [CrossRef] [PubMed] [Google Scholar]
  12. Damelin M, Bankovich A, Bernstein J, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med 2017; 9. [Google Scholar]
  13. Kung JE, Jura N. Prospects for pharmacological targeting of pseudokinases. Nat Rev Drug Discov 2019 ; 18 : 501–526. [PubMed] [Google Scholar]
  14. Liu M, Ma W, Li Q, et al. Aptamer-targeted DNA nanostructures with doxorubicin to treat protein tyrosine kinase 7-positive tumours. Cell Prolif 2019 ; 52 : e12511. [CrossRef] [PubMed] [Google Scholar]
  15. Karvonen H, Perttila R, Niininen W, et al. Targeting Wnt signaling pseudokinases in hematological cancers. Eur J Haematol 2018 ; 101 : 457–465. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.